New England Journal of Medicine Publishes 12-Week Results from Study Evaluating Atogepant for the Preventive Treatment of Migraine
ABBVie today announced that the New England Journal of Medicine has published 12-week results from the Phase 3 ADVANCE trial evaluating atogepant for the preventive treatment of migraine in adults who meet criteria for episodic migraine. The study, which enrolled adult participants experiencing 4 to 14 migraine days per month, found that all active treatment arms of atogepant 10 mg, 30 mg, and 60 mg once-daily ...
United States City Of United Kingdom Peter Goadsby University Of California Los Angeles Virtual Migraine Trust International Symposium
Source: investingnews.com